Ascendis Pharma A/S Overview
Valuation check: ASND's ROE is 52.64%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow52.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Ascendis Pharma A/S posts a ROE of 52.64%. That is above the Healthcare sector average of 22.01%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 22.01% is typical. Ascendis Pharma A/S's 52.64% is higher that level. That is roughly 139.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Ascendis Pharma A/S's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 52.64%; use YoY and peer views to separate noise from signal.
Context for ASND's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.01%), and (3) consistency with growth and profitability. This page covers the first two; Ascendis Pharma A/S's other metric pages and overview cover the third.
Judging Ascendis Pharma A/S against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 52.64% here, then scan peer and history charts to see if the gap is persistent.
